🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Delineation of Target Volume of Stereotactic Radiotherapy for Spinal Tumors

Recruitingn/aAges 18 Years - 90 YearsAllPeking University Third Hospital
NCT06587022 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The purpose of this study was to compare efficacy and side effects of two target delineation methods for stereotactic radiotherapy of metastatic spinal tumors.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients with spinal metastases or primary tumors receiving stereotactic radiotherapy; * Patients with sufficent pre-treatment imaging data * Patients who can cooperate with imaging review and follow-up after radiotherapy. Exclusion Criteria: * Patients with an expected survival of less than 3 months; * Patients with second-course radiotherapy; * Patients with physical conditions that cannot tolerate stereotactic radiotherapy; * Patients with extensive spinal metastasis and no local therapeutic value
💊

What it tests

  • Target volume delineation
📍

Where

1 site
Department of Radiation Oncology Cancer Center, Peking University Third Hospital 49# North Garden Rd.,Haidian Dist.
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy